bioAffinity Technologies Partners With Brooke Army Medical Center on CyPath Lung Validation Study

Reuters02-25 21:31
bioAffinity Technologies Partners With Brooke Army Medical Center on CyPath Lung Validation Study

bioAffinity Technologies Inc. has launched a validation study with Brooke Army Medical Center to assess the use of its CyPath Lung test on sputum samples collected via tracheal and bronchial suctioning. The study is expected to enroll about 30 to 50 patients, with results anticipated by mid-2026, and could broaden sample collection options to support earlier lung cancer detection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260225252955) on February 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment